These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31630241)

  • 41. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
    Dutton JJ; Buckley EG
    Ophthalmology; 1988 Nov; 95(11):1529-34. PubMed ID: 3211461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Botulinum toxin A: experience in the treatment of 115 patients].
    Andrade LA; Borges V; Ferraz HB; Azevedo-Silva SM
    Arq Neuropsiquiatr; 1997 Sep; 55(3B):553-7. PubMed ID: 9629404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?
    Boyle MH; McGwin G; Flanagan CE; Vicinanzo MG; Long JA
    Ophthalmic Plast Reconstr Surg; 2009; 25(2):81-4. PubMed ID: 19300145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
    Kiripolsky MG; Peterson JD; Guiha I; Goldman MP
    Dermatol Surg; 2011 Oct; 37(10):1443-7. PubMed ID: 21649790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.
    Czyz CN; Burns JA; Bergstrom RE
    J Neuroophthalmol; 2021 Dec; 41(4):e684-e687. PubMed ID: 33470741
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meige's syndrome: A cranial dystonia treated with bilateral pallidal deep brain stimulation.
    Markaki E; Kefalopoulou Z; Georgiopoulos M; Paschali A; Constantoyannis C
    Clin Neurol Neurosurg; 2010 May; 112(4):344-6. PubMed ID: 20061080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
    Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
    Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
    [No Abstract]   [Full Text] [Related]  

  • 48. Meige's syndrome: History, epidemiology, clinical features, pathogenesis and treatment.
    Pandey S; Sharma S
    J Neurol Sci; 2017 Jan; 372():162-170. PubMed ID: 28017205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin.
    Mauriello JA
    Neurology; 1985 Oct; 35(10):1499-500. PubMed ID: 4033932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige's syndrome.
    Møller E; Werdelin LM; Bakke M; Dalager T; Prytz S; Regeur L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Nov; 96(5):544-9. PubMed ID: 14600688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.
    Tolosa E; Martí MJ
    Adv Neurol; 1988; 49():73-84. PubMed ID: 3278555
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
    Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
    JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
    Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
    J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of Parkinson's disease in patients with blepharospasm.
    Micheli F; Scorticati MC; Folgar S; Gatto E
    Mov Disord; 2004 Sep; 19(9):1069-1072. PubMed ID: 15372598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
    Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
    Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
    Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
    J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA at the 1: 3 conversion ratio for the treatment of asymmetry after long-term facial paralysis.
    do Nascimento Remigio AF; Salles AG; de Faria JCM; Ferreira MC
    Plast Reconstr Surg; 2015 Jan; 135(1):239-249. PubMed ID: 25285681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation.
    Dursun N; Akarsu M; Gokbel T; Akyuz M; Karacan C; Dursun E
    J Rehabil Med; 2019 May; 51(5):390-394. PubMed ID: 30931483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.